Candida auris fungal infections increased 95% in 2021, and drug-resistant cases are continuing to spread across the US.
Candida auris is spreading rapidly throughout the United States, according to the Centers for Disease Control and Prevention (CDC).
Since it was first reported in 2016, C auris has been steadily spreading in the US. However, a new
The study utilized CDC national surveillance data from individuals with any specimen that tested positive for C auris. A total of 3270 clinical cases and 7413 screening cases of C auris were reported in the US through December 31, 2021. Each year, the percentage of clinical cases increased, with a 44% increase in 2019 and a 95% increase in 2021.
Additionally, 2021 saw an 80% increase in colonization screening volume and a more than 200% increase in screening cases. From 2019-2021, 17 states all identified their first-ever C auris case.
Echinocandins are a class of antifungals widely used to treat invasive candidiasis, primarily indicated for critically ill and neutropenic patients. Concerningly, this report found that the number of C auris cases with echinocandins resistance in 2021 had tripled in each of the preceding 2 years.
One limitation of these findings is that the identification of screening cases directly relies on the basis of need and available resources, which determine when screening is conducted. Because screening is not conducted uniformly across the country, the true burden of C auris cases is likely underestimated.
The investigators note that the rise in echinocandin-resistant cases and evidence of transmission are particularly alarming. “These findings highlight the need for improved detection and infection control practices to prevent spread of C auris,” they concluded.
